Risk of incident fragility fractures in a population of 5415 older adults according to circulating levels of cardiovascular biomarkers, CT-proAVP, CT-proET-1, MR-proADM and MR-proANP, in a Cox regression model
| Biomarkers | Unadjusted | Adjusted for age and gender | Fully adjusted* | |||
| HR (95% CI)† | C-statistic | HR (95% CI)† | C-statistic | HR (95% CI)† | C-statistic | |
| CT-proAVP | 0.99 (0.93 to 1.06) | 0.504 (0.432–0.611) | 1.06 (0.99 to 1.13) | 0.641 (0.543–0.766) | 1.04 (0.98 to 1.12) | 0.666 (0.555–0.787) |
| CT-proET-1 | 1.30 (1.23 to 1.39) | 0.574 (0.448–0.698) | 1.19 (1.11 to 1.28) | 0.647 (0.544–0.770) | 1.15 (1.07 to 1.23) | 0.668 (0.556–0.789) |
| MR-proADM | 1.37 (1.29 to 1.45) | 0.577 (0.450–0.693) | 1.21 (1.13 to 1.29) | 0.649 (0.544–0.772) | 1.21 (1.12 to 1.31) | 0.670 (0.559–0.795) |
| MR-proANP | 1.34 (1.26 to 1.43) | 0.580 (0.455–0.698) | 1.19 (1.11 to 1.28) | 0.646 (0.543–0.770) | 1.19 (1.10 to 1.28) | 0.669 (0.556–0.793) |
*Adjusted for age, gender, body mass index, systolic blood pressure, heart rate, antihypertensive treatment, diabetes, smoking, prevalent fractures, history of cardio/cerebrovascular disease and self-reported physical activity.
†HR is reported per 1 SD increase of log-transformed biomarker concentration.
CT-proAVP, copeptin; CT-proET-1, C-terminal endothelin-1; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide.